HIV type-1 (HIV-1) protease (PR) and cleavage site (CS) mutations accumulate in protease-inhibitor-resistant isolates. HIV-1 CS mutation 431V is the most frequent treatment-associated CS mutation; however, little is known about its origin in treatment-naive HIV-1 isolates. Recently, it has been shown that the CS mutation 431V is located within the human leukocyte antigen (HLA)-B*13-restricted cytotoxic T- lymphocyte (CTL) epitope RQANFLGKI (RI9). Therefore, we investigated whether the presence of CS mutation 431V might additionally be related to immune escape.
Methods
CTL recognition of RI9 and of RI9 variants carrying the 431V or the 436R mutation was analysed by ELISPOT in nine HLA-B*13-positive HIV-1-infected patients. Treatment-naive HIV-1-infected patients with primary drug-resistant HIV-1 isolates (n=58) or carrying 431V (n=4) were genotyped for HLA class I alleles.
Results
ELISPOT analysis showed different patterns of CTL recognition of RI9. CS mutation 431V could abrogate recognition by RI9-specific CTL in a subgroup of patients. Nevertheless, in our study, the occurrence of 431V in treatment-naive HIV-1 without primary drug resistance could not be explained by HLA-B*13-mediated immune selection. In patients with primary drug-resistant HIV-1 isolates, the frequency of HLA-B*13 was not increased and HLA-B*13 did not correlate with CS mutations 436R or 431V.
Conclusions
HIV-1 CS mutation 431V can abrogate CTL recognition, indicating interactions between development of drug resistance and the CTL response. However, we could not find evidence that the presence of 431V in treatment-naive HIV-1 isolates with and without primary drug resistance is related to immune selection by HLA-B*13 or other HLA class I alleles.
References
1.
DamE., QuerciaR., GlassB.Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.PLoS Pathog2009; 5: e1000345.
2.
ParryC.M., KohliA., BoinettC.J., TowersG.J., McCormickA.L., PillayD.Gag determinants of fitness and drug susceptibility in protease inhibitor resistant HIV-1.J Virol2009; 83: 9094–9101.
3.
NijhuisM., van MaarseveenN.M., LastereS.A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.PLoS Med2007; 4: e36.
4.
MuellerS.M., SchaetzB., EismannK.Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.J Virol2007; 81: 2887–2898.
5.
Schmitt-HaendleM., BachmannO., HarrerE., SchmidtB., BauerleM., HarrerT.Recognition patterns of HLA-A2-restricted human immunodeficiency virus-1-specific cytotoxic T-lymphocytes in a cohort of HIV-1-infected individuals.Viral Immunol2005; 18: 627–636.
6.
SamriA., HaasG., DuntzeJ.Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.J Virol2000; 74: 9306–9312.
7.
SabbajS., BansalA., RitterG.D.Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities.J Acquir Immune Defic Syndr2003; 33: 426–438.
8.
HoneyborneI., PrendergastA., PereyraF.Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple Gag-specific CD8+ T-cell epitopes.J Virol2007; 81: 3667–3672.
9.
TangJ., TangS., LobashevskyE.Favorable and unfavorable HLA class I alleles and haplotypes in Zambians predominantly infected with clade C human immunodeficiency virus type 1.J Virol2002; 76: 8276–8284.
10.
PradoJ.G., HoneyborneI., BrierleyI., PuertasM.C., Martinez-PicadoJ., GoulderP.J.Functional consequences of human immunodeficiency virus escape from an HLA-B*13-restricted CD8+ T-cell epitope in p1 Gag protein.J Virol2009; 83: 1018–1025.
11.
VerheyenJ., LitauE., SingT.Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-Gag in therapy-naive and therapy-experienced patients.Antivir Ther2006; 11: 879–887.
12.
VerheyenJ., KnopsE., KupferB.Prevalence of C-terminal Gag cleavage site mutations in HIV from therapy-naive patients.J Infect2009; 58: 61–67.
13.
OetteM., KaiserR., DaumerM.Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing.J Acquir Immune Defic Syndr2006; 41: 573–581.
14.
ShaferR.W., RheeS.Y., PillayD.HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.AIDS2007; 21: 215–223.
15.
BennettD.E., CamachoR.J., OteleaD.Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.PLoS ONE2009; 4: e4724.
16.
MyintL., MatsudaM., MatsudaZ.Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.Antimicrob Agents Chemother2004; 48: 444–452.
17.
NijhuisM., WensingA.M., BiermanW.F.Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.J Infect Dis2009; 200: 698–709.
18.
van MaarseveenN.M., SchipperP.J., de JongD., BoucherC.A.B., NijhuisM.Gag NC/p1 protease resistance mutations can cause selection of additional NC/p1 changes to optimize cleavage efficiency and replicative capacity.XVII International HIV Drug Resistance Workshop. 10–14 June 2008, Sitges, Spain. Abstract 47.
19.
MammanoF., PetitC., ClavelF.Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients.J Virol1998; 72: 7632–7637.
